Table 1.

Demographic and clinical characteristics of participants

Variable	PD-RBD	PD-nRBD	Controls	P
Age, y	66.7 (7.6)	63.1 (8.9)	63.3 (8.1)	0.36*
Men, n (%)	10 (67)	5 (33)	25 (61)	0.14†
Education, y	14.2 (3.6)	15.7 (3.9)	14.6 (4.1)	0.56*
PD duration, diagnosis, y	3.9 (2.9)	3.7 (2.6)	–	0.85‡
% tonic REM sleep motor activity	56.3 (33.8)	23.0 (32.5)	–	0.01 §
% phasic REM sleep motor activity	38.6 (17.3)	19.8 (16.9)	–	0.004 §
UPDRS-III, total “ON” state	24.1 (10.0)	17.6 (8.5)	–	0.08‡
Levodopa equivalent dosage, mg	625.2 (347.1)	447.8 (171.5)	–	0.65§
Levodopa use, %	87	93	–	0.54||
Dopamine agonist use, %	47	40	–	0.71||
MCI, %	53	27	–	0.14||

Data are presented as mean (SD). Bold values represent significant between-group differences.

MCI = mild cognitive impairment; PD-RBD = Parkinson’s disease with REM sleep behavior disorder; PD-nRBD = PD without RBD; UPDRS-III = Unified Parkinson’s Disease Rating Scale, Part III.

*Analysis of variance.

^†Fisher–Freeman–Halton exact test for contingency.

^‡Student’s t-test.

^§Mann–Whitney U test.

^||Chi-squared test.